Faruqi & Faruqi Urges PACS Group Investors About Class Action Participation Before Deadline

Important Class Action Reminder for PACS Group Investors

Faruqi & Faruqi, LLP, an esteemed national securities law firm, has recently brought attention to the pending class action lawsuit aimed at PACS Group, Inc. (NYSE: PACS). Investors who have incurred losses exceeding $50,000 are encouraged to explore their legal options as the deadline for selecting a lead plaintiff approaches on January 13, 2025.

James (Josh) Wilson, a partner at Faruqi & Faruqi, is actively reaching out to potential claimants, underscoring the importance of discussing options available to those affected by PACS Group's stock fluctuations.

Background on PACS Group and Recent Developments

PACS Group executed its initial public offering (IPO) on April 11, 2024, pricing shares at $21.00 each, culminating in net proceeds of roughly $450 million. However, following a series of alarming allegations regarding misleading business practices, the financial health of PACS Group has come into question.

The class action stems from claims asserting that PACS Group engaged in several deceptive practices, including the submission of false Medicare claims, which supposedly accounted for over 100% of the company’s operating and net income from 2020 through 2023. On September 3, 2024, the company filed for a secondary public offering, which profiled numerous transactions of common stock that raised further concerns about transparency and governance.

Notably, a contentious report published by Hindenburg Research on November 4, 2024, asserted that the company abused regulatory waivers in a scheme to inflate revenues through fraudulent billing for unnecessary medical services. As a result, PACS Group stock plummeted by more than 27% in value. Just days later, on November 6, the company announced a postponement of its fiscal third quarter earnings, following receipt of civil investigative demands from federal authorities, causing another drastic drop of nearly 39% in stock price.

The Class Action Process and Timeline

As proceedings unfold, potential class members are reminded of their rights: they can either nominate themselves as lead plaintiff, which entails taking an active role in the litigation, or remain passive participants maintaining eligibility for any potential recovery. The lead plaintiff will coordinate with the law firm and guide the litigation to represent the collective interests of the class. Those interested in advocating for their rights should not hesitate to reach out to Faruqi & Faruqi by calling their offices directly.

Call to Action for Investors

For individuals who have experienced losses tied to PACS Group’s stock performance, now is the time to evaluate your standing and consider joining the class action. Josh Wilson encourages direct communication from investors to assess the viability of claims related to the stock acquired during the class period, which extends from April 11, 2024, to November 5, 2024.

In light of ongoing litigation, any additional insights into PACS Group's operations from former employees or whistleblowers will be invaluable. Interested parties should connect with law firm representatives to share information.

For further information regarding this ongoing situation and exploratory avenues, please visit www.faruqilaw.com/PACS or get in touch with Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). This is an essential moment for impacted investors, and understanding your rights could be crucial as the class action develops.

About Faruqi & Faruqi, LLP

Since its establishment in 1995, Faruqi & Faruqi, LLP has forged a reputation as a formidable national law firm focused on securities litigation, recovering hundreds of millions for investors. Their consistent commitment to legal excellence and vigorous advocacy underscores their role as a trusted ally in the financial community. For ongoing updates, investors can follow the firm on LinkedIn, X, and Facebook.

Attorney Advertising: Past results do not guarantee a similar outcome in future matters. All communications are confidential.